Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ssCART-19 in Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT04825496Phase 1Unknown
- Sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd.
- Start
- Apr 2021
- Primary completion
- Dec 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ssCART-19 in acute lymphoblastic leukemia (ALL), sponsored by Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd. Primary endpoint: Dose Limiting Toxicity at 28 days. Status: unknown.
02
Drugs
ssCART-19
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT04825496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04825496.